Jackson Hole Capital Partners LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Jackson Hole Capital Partners LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,574 shares of the biopharmaceutical company’s stock after acquiring an additional 2,201 shares during the quarter. Jackson Hole Capital Partners LLC’s holdings in Gilead Sciences were worth $3,194,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GILD. Swedbank AB grew its position in Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after acquiring an additional 189,622 shares in the last quarter. Principal Financial Group Inc. grew its position in Gilead Sciences by 4.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,451,249 shares of the biopharmaceutical company’s stock valued at $121,673,000 after acquiring an additional 59,181 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in Gilead Sciences in the 3rd quarter valued at about $144,000. CWA Asset Management Group LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $6,353,000. Finally, Rovin Capital UT ADV grew its position in Gilead Sciences by 14.5% in the 3rd quarter. Rovin Capital UT ADV now owns 9,659 shares of the biopharmaceutical company’s stock valued at $810,000 after acquiring an additional 1,226 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GILD. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. UBS Group upped their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Mizuho upped their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Wolfe Research initiated coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Finally, Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.24.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $117.41 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $118.42. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a 50 day simple moving average of $99.61 and a 200-day simple moving average of $91.50. The stock has a market capitalization of $146.22 billion, a PE ratio of 317.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.69%. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 293,356 shares of company stock worth $29,166,240. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.